Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients

Bone Marrow Transplantation volume 37, pages 277–282 (2006)Cite this article

Abstract

From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT). Patients received fixed dose G-CSF 300 μg SC bid starting 24–36 h after finishing mobilizing ESHAP. In all, four patients failed mobilization and are excluded. Characteristics of 127 patients: 68 males: 59 females. DLCL 49: HD 78. Initial stage I:II:III:IV:unknown was 15:34:33:42:3. Median age at ASCT 26 years. Median prior chemotherapy cycles were six {<6 (17 patients), 6–8 (90 patients), >8 (20 patients)}. Median ESHAP cycle used as mobilizer was third. Patients required 1, 2, 3, 4 apheresis were 93:25:8:1. Median total CD34+ cells/kg collected were 6.9 × 106 (DLCL 5.17 × 106 and HD 7.6 × 106), patients weighing ⩽70 kg (93 patients) 6.54 × 106 and >70 kg (34 patients) 7.44 × 106 (P=0.59), one apheresis (93 patients) 8.6 × 106/kg and >1 apheresis (34 patients) 4.5 × 106 (P=0.001). We conclude that ESHAP and G-CSF 300 μg SC bid is an effective mobilizing regimen even in patients >70 kg and most patients require only 1–2 apheresis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Richman C, Weiner R, Yankee R . Increase in circulating stem cells following chemotherapy. Blood 1977; 47: 1031–1039.

    Google Scholar 

  2. Duhrsen U, Villeval J, Boyd J, Kannourakis G, Morstyn G, Metcalf D . Effects of recombinant Granulocyte Colony Stimulating Factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 10: 2074–2081.

    Google Scholar 

  3. Sheridan W, Begley C, To L, Grigg A, Szer J, Maher D et al. Phase II study of autologous filgastrim (G-CSF) mobilised peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105–111.

    CAS  PubMed  Google Scholar 

  4. Peters W, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C et al. Comparative effects of granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719.

    CAS  PubMed  Google Scholar 

  5. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064.

    Article  CAS  Google Scholar 

  6. To L, Roberts M, Haylock D, Dayson P, Branford A, Thorp D et al. Comparison of hematologic recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284.

    CAS  Google Scholar 

  7. Kessinger A, Sharp J . The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003; 31: 319–329.

    Article  CAS  Google Scholar 

  8. Vellenga E, van Agthoven M, Croockewit A, Verdonck L, Wijermans P, van Oers M et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114: 319–326.

    Article  CAS  Google Scholar 

  9. Glaspy J . Economic consideration in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 1999; 23: S21–S27.

    Article  Google Scholar 

  10. Dazzi C, Cariello A, Rosti G, Argnani M, Sebastiani L, Ferrari E et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma? Leuk Lymphoma 2000; 39: 301–310.

    Article  CAS  Google Scholar 

  11. Deliliers G, Annaloro C, Marconi M, Soligo D, Morandi P, Luchesini C et al. Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymphoma 2002; 43: 1957–1960.

    Article  CAS  Google Scholar 

  12. Kotasek D, Shepherd K, Sage R, Dale B, Norman J, Charles P et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17.

    CAS  PubMed  Google Scholar 

  13. McQuaker I, Haynes A, Stainer C, Anderson S, Russell N . Stem cell mobilization in resistant or relapsed lymphoma. Superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228–233.

    Article  CAS  Google Scholar 

  14. Morton J, Morton A, Bird R, Hutchins C, Durrant S . Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leukemia Res 1997; 21: 21–27.

    Article  CAS  Google Scholar 

  15. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290.

    Article  CAS  Google Scholar 

  16. Shepherd K, Charles P, Sage R, Dale B, Norman J, Kotasek D et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 1991; 13: 25–32.

    Article  CAS  Google Scholar 

  17. Watts M, Sullivan A, Jamieson E, Pearce R, Fielding A, Devereux S et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–546.

    Article  CAS  Google Scholar 

  18. Magagnoli M, Sarina B, Balzarotti M, Castagna L, Timofeeva I, Nozza A et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001; 28: 923–927.

    Article  CAS  Google Scholar 

  19. Petit J, Boque C, Cancelas J, Sarra J, Munoz J, Garcia J et al. Feasibility of ESHAP+G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leuk Lymphoma 1999; 34: 119–1127.

    Article  CAS  Google Scholar 

  20. Watts M, Ings S, Leverett D, MacMillan A, Devereux S, Goldstone A et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278–282.

    Article  CAS  Google Scholar 

  21. Zinzani P, Tani M, Molinari A, Stefoni V, Zuffa E, Alinari L et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87: 816–821.

    CAS  PubMed  Google Scholar 

  22. Akhtar S, El Weshi A, Rahal M . ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilisation regimen in patients with relapsed or refractory diffuse large cell and Hodgkin lymphoma: a single institution result of 100 patients. Bone Marrow Transplant 2004; 33: O259.

    Article  Google Scholar 

  23. Velasquez W, McLaughlin P, Tucker S, Hagemeister F, Swan F, Rodriguez M et al. E-SHAP an effective chemotherapy in refractory and relapsing lymphoma: a 4-year follow-up. J Clin Oncol 1994; 6: 1169–1176.

    Article  Google Scholar 

  24. Brocklebank A, Sparrow R . Enumeration of CD34 cells in cord blood: a variation on a single-platform flow cytometric method based on the ISHAGE gating strategy. Cytometry (Comm Clin Cytometry) 2001; 46: 254–261.

    Article  CAS  Google Scholar 

  25. Carlo-Stella C, Mangoni L, Piovani G, Garau D, Almici C, Rizzoli V . Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. Blood 1994; 83: 1373–1380.

    CAS  PubMed  Google Scholar 

  26. Andre M, Baudoux E, Bron D, Canon J, D'Hondt V, Fillet G et al. Phase III randomized study comparing 5 or 10 g per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50–57.

    Article  CAS  Google Scholar 

  27. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468–474.

    Article  CAS  Google Scholar 

  28. Weaver C, Birch R, Greco L, Schwartzberg L, McAneny B, Moore M et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338–347.

    Article  CAS  Google Scholar 

  29. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547–2555.

    Article  CAS  Google Scholar 

  30. Clark R, Brammer C . Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859–863.

    Article  CAS  Google Scholar 

  31. Drake M, Ranaghan L, Morris T, Nolan L, Desai Z, Irvine A et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745–749.

    Article  CAS  Google Scholar 

  32. Ford C, Chan K, Reilly W, Petersen F . An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003; 43: 622–625.

    Article  CAS  Google Scholar 

  33. Ford C, Green W, Warenski S, Petersen F . Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 2004; 33: 901–905.

    Article  CAS  Google Scholar 

  34. Micallef I, Apostolidis J, Rohatiner A, Wiggins C, Crawley C, Foran J et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367–373.

    Article  CAS  Google Scholar 

  35. Lee J-L, Kim S, Kim SW, Kim E-K, Kim S-B, Kang Y-K et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005; 35: 449–454.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We appreciate the assistance of Aneta Mclean from the apheresis lab and Ibrahim Abdullah Al-Hassan for statistical analysis.

Author information

Authors and Affiliations

  1. King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia

    S Akhtar, A Tbakhi, H Humaidan, A El Weshi, M Rahal & I Maghfoor

Authors
  1. S Akhtar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Tbakhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Humaidan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A El Weshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Rahal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Maghfoor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Akhtar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akhtar, S., Tbakhi, A., Humaidan, H. et al. ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 37, 277–282 (2006). https://doi.org/10.1038/sj.bmt.1705239

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705239

Keywords

This article is cited by

Search

Advanced search

Quick links